Journal
New England Journal of Medicine
Publication Date
6-8-2023
Volume
388
Issue
23
First Page
2145
Last Page
2158
Document Type
Open Access Publication
DOI
10.1056/NEJMoa2216334
Acceptable Secondary Publication – Plain Language Summary
https://www.tandfonline.com/doi/full/10.2217/fon-2023-0940
Rights and Permissions
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Copyright © 2023 Massachusetts Medical Society. Reprinted with permission.
Recommended Citation
Mirza, Mansoor R; McCourt, Carolyn; Powell, Matthew A; and et al., "Dostarlimab for primary advanced or recurrent endometrial cancer." New England Journal of Medicine. 388, 23. 2145 - 2158. (2023).
https://digitalcommons.wustl.edu/oa_4/2336
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
